









## **SMML** newsletter

**July 2023**Based on data from June 2023

Monthly updates around multiple myeloma























The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting on new developments on the other hand.





### Who will benefit from this newsletter?

Any professionals interested in keeping up with developments around multiple myeloma:


- Marketers
- **Business Analysts**
- But also HCPs who want to anticipate the future landscape of MM management




Introduction on Multiple Myeloma

## What is Multiple Myeloma?











### **Read more on Multiple Myeloma:**




- → Professional version in English
- → Professional version in French



- → Consumer version in English
- → Consumer version in French

## MM lines of therapy based on to the following definitions





## Drugs approved by European Medicines Agency (EMA)



Brand name	Active substance	Manufacturer	Class of therapy	EMA Date of authorisation	Line of treatment	Product Monograph
Revlimid®	lenalidomide	BMS	Immunomodulating agents (IMiDs)	14/06/2007	All lines	Click here
Thalidomide BMS® / Thalomid® (US)	thalidomide	BMS	Immunomodulating agents (IMiDs)	16/04/2008	All lines	<u>Click here</u>
Imnovid® / Pomalyst® (US)	pomalidomide	BMS	Immunomodulating agents (IMiDs)	05/08/2013	2L+ (after Revlimid and Velcade)	<u>Click here</u>
Pepaxti® / Pepaxto® (US)	melflufen	Oncopeptides AB	Peptide conjugated alkylator	17/08/2022	Triple class exposed / 3L+ / 4L+ / 5L+	<u>Click here</u>
Velcade®	bortezomib	Janssen	Proteasome inhibitors (PIs)	26/04/2004	1LSCT / 1LNSCT	<u>Click here</u>
Kyprolis®	carfilzomib	Amgen	Proteasome inhibitors (PIs)	19/11/2015	2L+ / 3L+	<u>Click here</u>
Ninlaro®	ixazomib	Takeda	Proteasome inhibitors (PIs)	21/11/2016	2L+	<u>Click here</u>
Farydak <sup>®</sup>	panobinostat	Novartis + (Secura Bio)	Histone deacetylase inhibitors (HDACis)	28/08/2015	2L+ Relapsed / Refractory	<u>Click here</u>
Darzalex <sup>®</sup>	daratumumab	Janssen	Monoclonal antibody against CD38 (Mabs)	20/05/2016	All lines	<u>Click here</u>
Empliciti <sup>®</sup>	elotuzumab	BMS + (AbbVie)	Monoclonal antibody against SLAMF7 (Mabs)	11/05/2016	2L+ / 3L+	<u>Click here</u>
Sarclisa®	isatuximab	Sanofi	Monoclonal antibody against CD38 (Mabs)	30/05/2020	2L+ / 3L+	Click here
Tecvayli®	teclistamab	Janssen	BiTE	21/07/2022	2L+ / 3L+	<u>Click here</u>
Blenrep® / Belamaf® (US)	belantamab mafodotin-blmf	GSK	Antibody-drug conjugates (BCMA)	25/08/2020	2L+ (4L+ after P, IMiD and MAB (L5+ in Italy)	<u>Click here</u>
Nexpovio® / Xpovio® (US)	selinexor	Karyopharm Therapeutics	Nuclear export inhibitor (SINE)	26/03/2021	Penta-refractory (2xPI + 2xIMiDs + 1 Mab)	<u>Click here</u>
Venclyxto® / Venclexta® (US)	venetoclax	AbbVie	B-cell lymphoma 2 (BCL-2)	04/12/2016	2L+ (already used in CLL / AML treatments)	<u>Click here</u>
Abecma®	idecabtagene vicleucel	BMS	Cell-based gene therapy (CAR-T)	18/08/2021	Triple class exposed / 3L+ / 4L+ / 5L+	<u>Click here</u>
Carvykti <sup>®</sup>	ciltacabtagene autoleucel	Janssen	Cell-based gene therapy (CAR-T)	25/05/2022	L3 / L4+ / L5+	<u>Click here</u>
Aredia®	pamidronate	Novartis	Bisphosphonates for bone disease	31/10/1991	Supportive care / Long-term use (5+ years)	<u>Click here</u>
Zometa®	zoledronate	Novartis	Bisphosphonates for bone disease	20/03/2001	Supportive care / Long-term use (5+ years)	<u>Click here</u>
Prolia® + Xgeva®	denosumab	Amgen	Bisphosphonates for bone disease	26/05/2010 - 13/07/2011	Supportive care	Prolia® / Xgeva®
Mozobil®	plerixafor	Genzyme	Stem cell mobilazor	30/07/2009	Supportive care	<u>Click here</u>

#### MM treatment history timeline 1844 1947 1958 1962 1983 1984 **IMiDs** Pls Urethane Melphalan Autologous "Rhubarb & orange peel, Corticosteroids Vincristine **IMS** strengthening plaster to the chest, transplantation + Adriamycin a pound of blood removed & leeches + Dexamethasone Mabs applied for maintenance therapy". **HDACi** SINE **BCMA** 2012 2010 2005 2002 2013 1999 **CAR-T**

bendamustine


(Levact®)

pomalidomide

(Imnovid®/Pomalyst®)

carfilzomib

(Kyprolis® US)



lenalidomide

(Revlimid®)

bortezomib

(Velcade®)

thalidomide

### MM studies at APLUSA







per wave per country per year

4,5K **PATIENTS CHARTS** per wave

18k **PATIENTS CHARTS** per year (in EU5)



### Launching of a US pilot wave, Why?

- Needs from clients for MM US data
- Back data for EU5 for 15 years
- MM US market changing fast
- Different needs in the US market for labs (patients' ethnicity treatments gap as an example)

### APLUSA's added value

- Quarterly + month to month data collection (our competitors → only quarterly data)
- Market adaptability: adjusting our questionnaires and updating the list of treatments by including market trends on a monthly basis → **new CAR-Ts + BisAbs**
- Patient's full treatment history
- Deliverables with Power BI DID



June 2023





## CONTENTS

01.

News around clinical trials in phase II

Phase II Relapse/Refractory:
 Bispecific antibodies

02.

News around clinical trial s in Phase III

Phase III Relapse/Refractory: CAR-T 03.

Themes of discussion: HCPs

- SOV Themes of discussion
- Posts driving most engagement
- Focus on #ASCO23
- Focus ON #EHA23

04.

News articles overtime

- Volume of articles per volume of mentions
- Articles per themes

05.

**Market watch** 

Market watch





## SCOPE



The scope of the analysis is focused on mentions coming worldwide.\*



There were a total of 30K mentions from patients recorded during the listening period from June 1<sup>st</sup>, 2023, to June 30<sup>th</sup>, 2023.




A majority of mentions came from News (46%), Twitter (42%), Tumblr (7%), Forums (2%), Reddit (1%), Blogs (1%) and Instagram (1%).



A total of 8K unique authors were identified.

\*myeloma OR multiplemyeloma OR #mmsm OR #Myeloma\* OR #Curemyeloma\* OR #mmmrd OR #mmsm OR title: ("multiple myeloma" OR myeloma)



## Drugs in clinical trials (Phase II) monitored during the listening period

**Bispecific antibody T-cell redirecting** 

talquetamab

N/A

Molecule name	Commercial name	Class	Manufacturer	Trial names + link (ctrl + right click) / line of treatment / Combination being studied
lenalidomide	Revlimid®	immunomodulatory drugs (IMiDs)	BMS	GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) FORTE (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone NCT02969837 (ND): elotuzumab, carfilzomib, lenalidomide, dexamethasone MASTER (/): dexamethasone, lenalidomide, daratumumab, carfilzomib
pomalidomide	Imnovid® / Pomalyst® (US)	immunomodulatory drugs (IMiDs)	BMS	NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone ELOQUENT-3 (RR): elotuzumab plus pomalidomide, and dexamethasone
Bortezomib	Velcade <sup>®</sup>	Proteasome inhibitors	Takeda	<u>GRIFFIN</u> (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) <u>NCT03314181</u> (RR): Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib)
carfilzomib	Kyprolis®	Proteasome inhibitor	Amgen	<u>FORTE</u> (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone <u>NCT02969837</u> (ND): elotuzumab, carfilzomib, lenalidomide, dexamethasone <u>MASTER</u> (???): dexamethasone, lenalidomide, daratumumab, carfilzomib <u>Cardamon</u> (/): cyclophosphamide, dexamethasone, carfilzomib
daratumumab	Darzalex®	Monoclonal antibody anti-CD38	Janssen	GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd)  FORTE (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone  NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone  REBUILD (RR): Monotherapy  NCT03314181 (RR): Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib)  MASTER (/): dexamethasone, lenalidomide, daratumumab, carfilzomib  RedirecTT-1 (RR): Teclistamab, talquetamab, daratumumab (Note: Phase I/II currently in phase IB)
elotuzumab	Empliciti <sup>®</sup>	Monoclonal antibody SLAMF7	BMS/AbbVie	ELOQUENT-3 (RR): elotuzumab plus pomalidomide, and dexamethasone NCT02969837 (ND): elotuzumab, carfilzomib, lenalidomide, dexamethasone
isatuximab	Sarclisa®	Monoclonal antibody anti-CD38	Sanofi	NCT05123131 (ND): isatuximab, bortezomib, lenalidomide, dexamethasone NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone
belantamab mafodotin, (GSK2857916)	Blenrep <sup>®</sup>	Antibody drug-conjugate (ADC)	GSK	DREAMM-2 (RR): Monotherapy
Ciltacabtagene (cilta cel, JNJ 68284528)	Carvykti <sup>®</sup>	CAR T-Cell Therapy Anti-BCMA	Janssen	CARTITUDE (RR): Monotherapy CARTITUDE 2 (RR): Monotherapy
idecabtagene vicleucel (ide cel)	Abecma	CAR T-Cell Therapy Anti-BCMA	BMS	KarMMa-2 (RR): Monotherapy (one arm with lenalidomide)
Zevorcabtagene autoleucel (zevor cel)	N/A	CAR T-Cell Therapy Anti-BCMA	CARsgen Therapeutics	<u>LUMMICAR-2</u> (RR): Monotherapy
C-CAR088	N/A	CAR T-Cell Therapy Anti-BCMA	Cellular Biomedicine	NCT05521802 (RR): Monotherapy
teclistamab	Tecvayli®	Bispecific Antibody anti-BCMA	Janssen	MajesTEC-1: (RR): Monotherapy RedirecTT-1 (RR): Teclistamab, talquetamab, daratumumab (Note: Phase I/II currently in phase IB)


Janssen

MonumenTAL-1 (RR): Monotherapy

### Phase II Relapse/Refractory Bispecific antibodies: Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory **Multiple Myeloma**



### Clinical trial mentioned/Sponsor



## Headlines/Hot off the press

Janssen Presents First-Ever Results from Dual **Bispecific Combination Study Showing 96 Percent** Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI®, a first-in-class BCMAxCD3 bispecific antibody, and talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, showing a high overall response rate (ORR) among patients with relapsed or refractory multiple myeloma (RRMM). Click here to read the full article

Teclistamab Yielded Deep and Durable Responses for 99
Patients With R/R Multiple Myeloma

"At the 2023 ASCO (..) presented results from the long-term follow-up of the MajesTEC-1 trial, which indicated that teclistamab demonstrated deep and durable responses for patients with relapsed/refractory multiple myeloma. Click here to read the full article

99 | 66 MonumenTAL-1 Study Identifies Impressive Responses 99 to Talquetamab in Patients With Multiple Myeloma

> "At the 2023 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, Carolina Schinke, MD, University of Arkansas, Little Rock, Arkansas, discussed findings from the MonumenTAL-1 trial which indicated that patients with multiple myeloma, both with and without prior T-cell redirection therapy, had impressive responses to talquetamab, a GPRC5D-CD3 bispecific antibody. " Click here to read the full article

Elranatamab Induces Responses in Patients With Relapsed/Refractory Multiple Myeloma Following BCMA-**Directed Therapy** 

"Patients with relapsed/refractory multiple myeloma treated with elranatamab following any prior BCMA-directed therapy achieved an overall response rate of 46%." Click here to read the full article

#### RedirecTT-1

Ctrl + click to access clinical trial:

"A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma."

### MonumenTAL-1

Ctrl + click to access clinical trial: NCT04634552

"The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)."

### MajesTEC-1

Ctrl + click to access clinical trial: NCT04557098

"A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)"

### MagnetisMM-3

Ctrl + click to access clinical trial: NCT04649359

"Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb"

### Molecules

talquetamab + teclistamab +/- daratumumab

### talquetamab

teclistamab

elranatamab

Food and Drug Administration Satu Glawe Carolina Schinke Bhagirathbhail R. Dholaria muncherapy atology Association American Society of Clinical Oncology

Arnob Banerjee Prizer Amsterdam Janssen Mohity FDA Raychel Kruper Tecvayli Christine Corbest Talquetamab U.S. ASCOCHICAGO Christie Corbett Talquetamab Talquetamab RRMM Johnson Cohen USA Para Janssen Pharmaceutical Companies of Johnson

Niels Van de Donk

Janssen Oncology American Cancer Society

Phase II N= 605 mentions Social media listening period: June 2023 Scope: worldwide in English

## Drugs in clinical trials (Phase III) monitored during the listening period

Molecule name	Commercial name	Class	Manufacturer	Trial names + link (ctrl + right click) / line of treatment / Combination being studied
lenalidomide	Revlimid <sup>®</sup>	immunomodulatory drugs (IMiDs)	BMS	DETERMINATION (RR): lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD)  MAIA (ND): daratumumab in combination with lenalidomide and dexamethasone  ATLAS (Maintenance): Lenalidomide, Carfilzomib, Dexamethasone  DRAMMATIC (/): Lenalidomide, Daratumumab  EQUATE (ND): daratumumab, bortezomib, lenalidomide and dexamethasone  POLLUX (RR): Daratumumab, Lenalidomide, and Dexamethasone  TOURMALINE (RR): Ixazomib Plus Lenalidomide and Dexamethasone  Myeloma XI (ND): cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib  AURIGA (Maintenance): Daratumumab Plus Lenalidomide
pomalidomide	Imnovid® / Pomalyst® (US)	immunomodulatory drugs (IMiDs)	BMS	ICARIA-MM (RR): Isatuximab, Pomalidomide, Dexamethasone
bortezomib	Velcade <sup>®</sup>	Proteasome inhibitors (PIs)	Takeda	DETERMINATION (RR): lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD)  BOSTON (RR): selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd)  EQUATE (ND): daratumumab, bortezomib, lenalidomide and dexamethasone  CASTOR (RR): Daratumumab, Bortezomib and Dexamethasone  Bellini (RR): venetoclax plus bortezomib and dexamethasone  DREAMM 7 (RR): Belantamab Mafodotin, Bortezomib and Dexamethasone
carfilzomib	Kyprolis®	Proteasome inhibitors (PIs)	Amgen	IKEMA (RR): Isatuximab, Carfilzomib And Dexamethasone ATLAS (Maintenance): Carfilzomib, Lenalidomide, Dexamethasone Myeloma XI (ND): cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib
ixazomib	Ninlaro®	Proteasome inhibitors (PIs)	Takeda	OPTIMUM (RR): Ixazomib, Lenalidomide TOURMALINE (RR): Ixazomib Plus Lenalidomide and Dexamethasone
Bb2121, Idecabtagene vicleucel	Abecma®	CAR T-cell therapy	BMS	KarMMa-3 (RR): Monotherapy
ciltacabtagene	Carvykti <sup>®</sup>	CAR T-cell therapy BCMA-directed	Janssen	CARTITUDE-4 (RR): Monotherapy
daratumumab	Darzalex <sup>®</sup>	Monoclonal antibody anti-CD38	Janssen	MajesTEC-3: (RR): Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara)  MAIA (ND): daratumumab in combination with lenalidomide and dexamethasone  DRAMMATIC (/): Lenalidomide, Daratumumab  EQUATE (ND): daratumumab, bortezomib, lenalidomide and dexamethasone  CASTOR: (RR): Daratumumab, Bortezomib and Dexamethasone

				Myeloma XI (ND): cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib
ixazomib	Ninlaro®	Proteasome inhibitors (PIs)	Takeda	OPTIMUM (RR): Ixazomib, Lenalidomide TOURMALINE (RR): Ixazomib Plus Lenalidomide and Dexamethasone
Bb2121, Idecabtagene vicleucel	Abecma <sup>®</sup>	CAR T-cell therapy	BMS	KarMMa-3 (RR): Monotherapy
ciltacabtagene	Carvykti <sup>®</sup>	CAR T-cell therapy BCMA-directed	Janssen	CARTITUDE-4 (RR): Monotherapy
daratumumab	Darzalex <sup>®</sup>	Monoclonal antibody anti-CD38	Janssen	Majestec-3: (RR): Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara)  MAIA (ND): daratumumab in combination with lenalidomide and dexamethasone  DRAMMATIC (/): Lenalidomide, Daratumumab  EQUATE (ND): daratumumab, bortezomib, lenalidomide and dexamethasone  CASTOR: (RR): Daratumumab, Bortezomib and Dexamethasone  POLLUX (RR): Daratumumab, Lenalidomide, and Dexamethasone  MagnetisMM-5 (RR): Monotherapy or doublet therapy with daratumumab  AURIGA (Maintenance): Daratumumab Plus Lenalidomide
isatuximab	Sarclisa®	Monoclonal antibody anti-CD38	Sanofi	IKEMA (RR): Isatuximab, Carfilzomib And Dexamethasone ICARIA-MM (RR): Isatuximab, Pomalidomide, and Dexamethasone
belantamab mafodotin-blmf	Blenrep® / Belamaf® (US)	Antibody-drug conjugates (BCMA)	GSK	<u>DREAMM-3</u> (RR): Monotherapy <u>DREAMM 7</u> (RR): Belantamab Mafodotin, Bortezomib and Dexamethasone <u>DREAMM 8</u> (RR): Belantamab Mafodotin Plus Pomalidomide and Dexamethasone

Phase III Relapse/Refractory CAR-T: Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study



### Headlines/Hot off the press

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

"Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that results from the Phase 3 CARTITUDE-4 study showed that, at a median follow up of 16 months, cilta-cel reduced the risk of disease progression or death by 74 percent compared to standard of care regimens in adult patients with multiple myeloma who have received one to three prior lines of therapy and are refractory to lenalidomide (Hazard ratio [HR]=0.26 (95% CI, 0.18-0.38); P-value [P] < 0.0001)."

Sponsor





CARTITUDE-4
Ctrl + click to access clinical
trial: NCT04181827

"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma"

Molecule


Ciltacabtagene autoleucel






Discussions around #ASCO23 took centre stage this month with the CAR-T cilta-cel emerging as the top drug in term of mention amongst HCPs.

### SOV topics of conversations



### SOV molecules










The posts receiving the most engagement this month were tangentially about ASCO 2023, providing treatment information as well as highlighting personal achievements.

Dr Rajkumar both got the most retweeted and liked posts this month.

He focused on providing educational posts first for ASCO 2023 on how he treats multiple myeloma. The other tweet, posted later in the month, provides a selection of his most important insights about MM, its diagnostic, treatment etc.

The most replied to tweet was also about ASCO 2023 where Dr Al Hadidi received the health equity disruptive innovator award for 2023.





## #ASCO23 Focus on Multiple Myeloma

## 2023 ASCO

This year's edition was heavily focused on **CAR-T** cell therapies and **bispecific** antibodies.

Highly anticipated results from the **CARTITUDE-4** reflect this. Other development of note include **teclistamab** and **talquetamab** and corresponding trials **RedirecTT-1** and **MajesTEC-1**.

#### **Volume of mentions**





ASCO 2023 1014 mentions


janssen )

janssen /


janssen )

REGENERON


#### Topics of discussions (type of treatment)



HCPs multiple myeloma ASCO 2023 universe N= 1 014 mentions Social media listening period: May 26th, 2023, to June 20th, 2023 Scope: worldwide in English




#### Top posts from HCPs per engagement





Can we speed up to CARs to arrive in less than 10 days? PHE885 may cross the finish line - and with an impressive response rate of 98%. Toxicity consistent with other CAR T. #ASCO2023 #MMSM #MedIQ23ASCO





## #EHA23 Focus on Multiple Myeloma

Overall bispecific antibodies **elranatamab** and **talquetamab** took center stage online during #eha23 with the results of Orion MagnetisMM-3 being particularly cited.


Influenced by the results from **CARTITUTE- 4** + additional results from **CARTITUDE-1**,
CAR-T therapies were also of high interest
with **cilta-cel** the most mentioned
molecule.


Volume of mentions

EHA 2022 271 mentions

EHA 2023 206 mentions

#### **Topics of discussions (type of treatment)**









Joseph Mikhae






HCPs multiple myeloma EHA 2023 universe N= 206 mentions Listening period: June 01st, 2023, to June 25th, 2023 Scope: worldwide in English

SYNDICATED BY

## Media (press releases): volume and articles per peak 1/2



## A

"Janssen Presents First-Ever Results from **Dual Bispecific Combination** Study Showing **96 Percent Overall Response** Rate in Patients with Relapsed or Refractory Multiple Myeloma" Link

"Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma" <u>Link</u>

"**Gracell Biotechnologies** Presents Updated Data of Deep and Durable Responses for **FastCAR-T GC012F** in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting" <u>Link</u>

### B

"Janssen Presents Longer-Term Data for **TECVAYLI®** (teclistamab-cqyv) Showing a **Duration of Response of 22 Months in Patients** with Relapsed or Refractory Multiple Myeloma" <u>Link</u>

"Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study" Link

"IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of **Equecabtagene Autoleucel** (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting" <u>Link</u>

"**Telo Genomics** Presents **Superior Results** of Its Smoldering Multiple Myeloma Studies at ASCO 2023" <u>Link</u>

"Investigators Report **Efficacy Trends With PHE885** in R/R Multiple Myeloma" <u>Link</u>


"Linvoseltamab Elicits Positive Efficacy in R/R Multiple Myeloma"  $\underline{\text{Link}}$ 

"Single-Agent **Elranatamab** Garners **Robust, Durable Responses in Advanced Myeloma**" <u>Link</u>

## Media (press releases): volume and articles per peak 2/2







"Antengene Announces XPOVIO plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma" link

"**Molecular Templates** Announces the **FDA Removal** of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma" <u>Link</u>

**"The International Myeloma Foundation (IMF)** Honors 2023 Research Achievement Awardees, Dr. Maria-Victoria Mateos and Dr. Thomas Martin" Link

"New multiple myeloma cell therapy is yielding dramatic results" Link

## +

## **Bispecific antibody**

- "Janssen Presents Longer-Term Talquetamab
  Follow-Up Data Showing Overall Response Rates of
  More Than 70 Percent in Heavily Pretreated Patients
  with Multiple Myeloma" <u>Link</u>
- "Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma" <u>Link</u>
- "Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma" <u>Link</u>
- "Linvoseltamab Elicits Positive Efficacy in R/R Multiple Myeloma" <u>Link</u>
- "Single-Agent Elranatamab Garners Robust, Durable Responses in Advanced Myeloma" <u>Link</u>

## **CAR T-cell therapy**

- "Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FastCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting" <u>Link</u>
- "New multiple myeloma cell therapy is yielding dramatic results" Link
- "Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study" <u>Link</u>
- "IASO Bio and Innovent Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting" <u>Link</u>
- "Investigators Report Efficacy Trends With PHE885 in R/R Multiple Myeloma" <u>Link</u>

## **Engineered Toxin Body (ETB)**

"Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma" Link

### Misc.

"The International Myeloma Foundation (IMF)
Honors 2023 Research Achievement Awardees, Dr.
Maria-Victoria Mateos and Dr. Thomas Martin" <u>Link</u>

## **Nuclear export inhibitor**

"Antengene Announces XPOVIO plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma" <a href="mailto:link">link</a>

## **Smoldering Multiple Myeloma**

"**Telo Genomics** Presents **Superior Results** of Its Smoldering Multiple Myeloma Studies at ASCO 2023" Link

## **Drug Market Watch**

May/June 2023



66 Janssen Seeks European Commission 99
Approval of a New Indication for
CARVYKTI® (ciltacabtagene
autoleucel; cilta-cel) for the Earlier
Treatment of Patients with Relapsed
and Refractory Multiple Myeloma Link



Jemperli • **Xpovio** secure the reimbursements in Korea, criteria applied Link



FDA Grants Fast Track Designation to Inobrodib in R/R Multiple Myeloma Link

Janssen Submits Supplemental Biologics License Application to U.S. FDA Seeking Approval of CARVYKTI® for the Earlier Treatment of Patients with Relapsed or Refractory Multiple Myeloma Link



66 Antengene Announces **XPOVIO**® plus Bortezomib and 99 Dexamethasone Included for Reimbursement by the PBS in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma Link



## Back from EHA - Frankfurt 2023

Poster presentation and

live webinar with Dr. BLIN

July 2023

## 0

## Back from EHA 2023 – AplusA and Dr. BLIN presented MM poster during the congress



**Dr. Nicolas BLIN**, hematologist at Nantes University Hospital, accompanied our experts and had the opportunity to present the poster:

# ACTUAL USAGE OF CURRENT SYSTEMIC TREATMENTS AND INFLUENCE OF KEY DRIVERS FOR MULTIPLE MYELOMA IN THE FIRST 2 LINES OF THERAPY. DATA FROM REAL-WORLD STUDY IN EU5 COUNTRIES

that he co-created with our AplusA experts Melissa YILMAZ and Siegfried ERTL.

You can download and access the poster by clicking the button below:



During the Friday evening poster session, Dr. BLIN presented the **results in a detailed video presentation**. Access the video by clicking the button below and learn more about our MM data from real-world study:



## 0

## Back from EHA 2023 – AplusA live webinar on Dr. BLIN's highlights from the congress



After the congress, we've held a live webinar with Dr. Nicolas BLIN who highlighted the key moments of the EHA.

Co-moderated by our experts Melissa YILMAZ and Siegfried ERTL, Dr. BLIN **presented the latest news on hematology**, **commented some abstracts based on ongoing clinical trials** and **shared his thoughts on different hot topics in hematology** (Multiple Myeloma, Acute Myeloid Leukemia, Myelofibrosis, bispecific antibodies, CAR T cell therapies, etc.)

